dotMD.com
Find a Doctor
✓ Translated by DotMD AI Clinical Council Source: Clinical nutrition (Edinburgh, Scotland) • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #41485450 ↗

Randomized Controlled Trial: Effects of 5:2 intermittent fasting meal replacement on body composition and abdominal fat distribution in overweight and obese adults with early type 2 diabetes (N = 85)

Original Paper Title: “Effects of 5:2 intermittent fasting meal replacement on body composition and abdominal fat distribution in overweight and obese adults with early type 2 diabetes”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 85
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The 5:2 MR regimen may be more effective than metformin and empagliflozin in improving body composition and abdominal fat distribution in early T2DM, and is proposed as a therapeutic option.
  • Study Design & Sample: Randomized Controlled Trial published in Clinical nutrition (Edinburgh, Scotland) (N = 85 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Clinical nutrition (Edinburgh, Scotland) (2026), this randomized controlled trial evaluating 85 human participants investigated: This analysis further investigated the exploratory outcomes related to body composition and abdominal fat distribution. Key clinical takeaway: The 5:2 MR regimen may be more effective than metformin and empagliflozin in improving body composition and abdominal fat distribution in early T2DM, and is proposed as a therapeutic option.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Clinical nutrition (Edinburgh, Scotland), 2026-02-15; N = 85; Rigor 82/100): The 5:2 MR regimen may be more effective than metformin and empagliflozin in improving body composition and abdominal fat distribution in early T2DM, and is proposed as a therapeutic option.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: metformin-hcl → Rx: metformin-hydrochloride → Rx: glucose-and-sodium-chloride-dextrose-anhydrous-and-sodium-chloride → Rx: empagliflozin → Condition: blood-glucose → Condition: diabetes →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 41485450: Randomized Controlled Trial: Effects of 5:2 intermittent fasting meal replacement on body composition and abdominal fat distribution in overweight and obese adults with early type 2 diabetes (N = 85)

3 of 3 Free Questions Remaining